Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q1 2022 · 10-Q
Revenue$8.23M$8.23M+40.1% vs Q1 2021 Net Income-$10.86M-$10.86MN/M vs Q1 2021 EPS Diluted-$0.75-$0.75N/M vs Q1 2021 Gross Profit$4,999,000+44.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flow-$10,430,000N/M Free Cash Flowderived-$10,766,000N/M Margins · derivedGross margin60.7%+1.8 pt vs Q1 2021
Operating margin-119.6%+4.1 pt vs Q1 2021
Net margin-132.0%+6.5 pt vs Q1 2021
ended Mar 31, 2022 · filed May 11, 2022 · 41 d after period end